CytoDyn Inc. (CYDY)
OTC Markets OTCQB
Price as at 30 Sept 2026, 17:26 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
CytoDyn Inc. trades at $0.21. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its CYDY data?
Fundamentals for CYDY come from company filings and exchange data, as listed on OTC Markets OTCQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:26 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CYDY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.